Navigation and service

Brain Tumours

The special field of interest of this group is the preclinical and clinical testing of new radiopharmaceuticals for the diagnosis of brain tumours (i.e., gliomas and metastasis) using positron emission tomography (PET) and correlated with magnetic resonance imaging (MRI). This includes the assessment of amino acid uptake in brain tumours, along with modern developments in functional MRI and the clinical application of correlative MR-PET imaging for diagnosis, therapy planning and therapy control in patients with brain tumours.

Additional fields of specialist interest include the evaluation of the therapeutic effects of novel amyloid-β binding peptide ligands using behavioural tests, PET and autoradiography.

Key cooperation partners:

Klinik und Poliklinik für Neurologie - Uniklinik Köln

Institut für Biologische Informationsprozesse Strukturbiochemie (IBI-7) - Forschungszentrum Jülich

Highlight 1:

Improved imaging of brain tumour extent

Magnetic resonance imaging (MRI) is the most important diagnostic tool for assessing brain neoplasms. Areas of contrast enhancement (CE) on MRI are often considered target volumes for surgery or radiation therapy in glioblastomas. However, the tumour may extend beyond areas of CE. PET, using the radiolabeled amino acid O-(2-[18F]fluoroethyl)-L-tyrosine (FET), provides important additional information in this regard. In a study of 50 patients, tumour tissue beyond CE was detected in 86% of cases. Thus, FET PET is an important method to improve therapy planning in brain tumours.

Lohmann P, Stavrinou P, Lipke K, Bauer EK, Ceccon G, Werner JM, Neumaier B, Fink GR, Shah NJ, Langen KJ, Galldiks N. FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma. Eur J Nucl Med Mol Imaging. 2019; 46:591-602

Improved imaging of brain tumour extent

Patient with glioblastoma. T1-weighted MRI (left) shows pathological contrast enhancement in the brain (CE). FET PET (centre) shows the tumour to be significantly larger (red area). Volumetric comparison (right) shows a tumour volume of 0.5 ml for CE and 14.3 ml in FET PET.

Highlight 2:

Correlative spectroscopic MR imaging and FET PET in brain tumours using hybrid PET-MRI 

Both FET PET and spectroscopic MR imaging (MRSI) can identify brain tumour tissue with higher accuracy than conventional MRI. In a hybrid PET MRI study of 41 patients with various brain tumours, tumour imaging was compared with FET PET and MRSI. Differences in tumour imaging with FET PET and MRSI were then shown based on choline/NAA distribution. The parameters obviously reflect different biological properties of the tumour. These will be further investigated in a current study in comparison to histological data. 

Mauler J, Maudsley AA, Langen KJ, Nikoubashman O, Stoffels G, Sheriff S, Lohmann P, Filss C, Galldiks N, Rota Kops E, Shah NJ. Spatial Relationship of Glioma Volume Derived from 18F-FET PET and Volumetric MRSI: a hybrid PET-MRI study. J Nucl Med. 2018; 59:603-609

Korrelative Bildgebung der spektroskopischen MR-Bildgebung und FET PET bei Hirntumoren mit der Hybrid PET-MRT

Multicentric oligodendroglioma showing larger extent of FET uptake than Cho/NAA abnormality in occipital lesion and smaller extent in parietal lesion. Overlay (right): blue: FET only, red:Cho/NAA only, yellow: intersection.

Additional Information

Brain Tumors

Group Leader

Prof. Dr. med. K.-J. Langen

Building: 15.2, Room: 372

phone: +49-2461-61-5900
fax: +49-2461-61-8261


Prof. Dr. med. K.-J. Langen
Prof. Dr. Martin Kocher
Priv.-Doz. Dr. rer. medic. Philipp Lohmann
Dr. med. Christian Filß
Dr. rer. medic. Stefanie Geisler
Dr. rer. nat Carina Stegmayr
Dr. med. Gabriele Stoffels
Dr. rer. nat. Antje Willuweit
Carina Balduin
Nicole Burda
Robin Gutsche
Natalie Judov
Monika Ollig
Friedrich Michel
Trude Plum
Michael Schöneck
Jin Wang
Group Photo


Institut für Neurowissenschaften und Medizin (INM-4)
Forschungszentrum Jülich
52425 Jülich
Gebäude: 15.2